T

he biotech market is frothy. I hesitate to scream “bubble” but it’s getting there. The early warning signs are clear in the way small-cap biotech stocks are running higher on hype and momentum. Common sense and fundamentals no longer seem to matter.

Today’s example: Catabasis Pharmaceuticals (CATB), which announced “positive” results from a failed study for a drug to treat boys with Duchenne muscular dystrophy. The stock is up 55 percent to $4.38 in pre-market trading.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X